Effect of clarithromycin alone and clarithromycin containing regimen for mycobacteriun avium complex pulmonary disease

Y. Yamaji, N. Nanki, T. Nagamura, M. Kaji, K. Miyatani (Kanonji, Japan)

Source: Annual Congress 2006 - Infections in immunocompromised patients
Session: Infections in immunocompromised patients
Session type: Poster Discussion
Number: 3212
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Yamaji, N. Nanki, T. Nagamura, M. Kaji, K. Miyatani (Kanonji, Japan). Effect of clarithromycin alone and clarithromycin containing regimen for mycobacteriun avium complex pulmonary disease. Eur Respir J 2006; 28: Suppl. 50, 3212

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I
Year: 2019




Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease
Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019
Year: 2020



Switch effects from daily to intermittent treatment with a daily regimen dosage for Mycobacterium avium complex pulmonary disease
Source: International Congress 2019 – Clinical and translational studies of bronchiectasis and non-TB mycobacterial infection
Year: 2019


In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis
Source: Eur Respir J 2014; 44: 808-811
Year: 2014


Treatment outcome of combination antibiotic therapy including clarithromycin for Mycobacterium avium complex pulmonary disease
Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis
Year: 2010

Susceptibility of mycobacterium avium complex and mycobacterium xenopi to rifampin, rifapentine, clarithromycin and moxifloxacin, alone or in combination with ethambutol
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011


High-dose rifampicin and rifapentine in tuberculosis treatment
Source: International Congress 2015 – Tuberculosis: short-course chemotherapy
Year: 2015



Comparison of safety and efficacy between clarithromycin- and azithromycin-containing regimens in Mycobacterium avium complex lung disease
Source: International Congress 2019 – Complex respiratory infections in clinical practice
Year: 2019

Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease
Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019
Year: 2019



A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004

Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 587s
Year: 2006

Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012

The role of moxifloxacin in tuberculosis therapy
Source: Eur Respir Rev 2015; 25: 19-28
Year: 2016



A double blind randomized study of aminoglycoside infusion with combined therapy for pulmonary mycobacterium avium complex disease
Source: Annual Congress 2006 - Clinical epidemiology of tuberculosis
Year: 2006


Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease
Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria
Year: 2018



Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 524s
Year: 2003

Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease
Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Year: 2020


Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients
Source: Eur Respir J 2013; 42: 1614-1621
Year: 2013



Efficacy and safety of kanamycin addition in patients with drug-refractory mycobacterium avium complex lung disease
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015


Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011